收购MSC干细胞疗法技术引发股价暴涨 Neuroscientific Biopharmaceuticals (ASX:NSB) 加速克罗恩病临试研究

澳洲财经见闻

Jul 19, 2025

神经免疫疾病生物医学创新公司Neuroscientific Biopharmaceuticals Ltd (ASX股票代码:NSB) 股价异动，周四飙涨16.67%。

自4月中旬披露收购间充质干细胞 (MSC) 治疗技术StemSmart以来，NSB股价上涨348.72%。

NSB最新价0.175澳元，已发行股本3.33亿股，市值5820万澳元。截止一季度末公司账面现金结余449万澳元。

美国FDA最近批准了首个MSC疗法——由市值达20亿澳元的澳洲生物科技公司Mesoblast(ASX股票代码:MSB)提请注册，该进展重新点燃医疗界对MSC疗法临床研究的热情并吸引全球投资者目光。

Neuroscientific Biopharmaceuticals 于6月底完成对StemSmart技术的收购。NSB即将上任的董事局主席Robert McKenzie表示，公司正在推动运用StemSmart治疗瘘管性克罗恩病的特别准入试验；若初步结果积极，将可推进至 1/2 期临试。

（图片来源：NSB公告）

（图片来源：NSB公告）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2552154364"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552154364\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552154364?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-19 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552154364","market":"hk","top_or_hot":-1,"title":"收购MSC干细胞疗法技术引发股价暴涨 Neuroscientific Biopharmaceuticals (ASX:NSB) 加速克罗恩病临试研究","media":"澳洲财经见闻","content":"<html><body><p>神经免疫疾病生物医学创新公司<strong>Neuroscientific Biopharmaceuticals Ltd (ASX股票代码:NSB) </strong>股价异动，周四飙涨16.67%。</p>\n<div>\n<div></div>\n</div>\n<p>自4月中旬披露收购间充质干细胞 (<a href=\"https://laohu8.com/S/NPW.SI\">MSC</a>) 治疗技术StemSmart以来，NSB股价上涨348.72%。</p>\n<p>NSB最新价0.175澳元，已发行股本3.33亿股，市值5820万澳元。截止一季度末公司账面现金结余449万澳元。</p>\n<p>美国FDA最近批准了首个MSC疗法——由市值达20亿澳元的澳洲生物科技公司<a href=\"https://laohu8.com/S/MESO\">Mesoblast</a>(ASX股票代码:MSB)提请注册，该进展重新点燃医疗界对MSC疗法临床研究的热情并吸引全球投资者目光。</p>\n<p>Neuroscientific Biopharmaceuticals 于6月底完成对StemSmart技术的收购。NSB即将上任的<strong>董事局主席Robert McKenzie</strong>表示，公司正在推动运用StemSmart治疗瘘管性克罗恩病的特别准入试验；若初步结果积极，将可推进至 1/2 期临试。</p>\n<figure><img decoding=\"async\" height=\"494\" src=\"https://static.tigerbbs.com/ec5e90405a53440890016f8c99cbe40b\" width=\"1024\"/></figure>\n<p>（图片来源：NSB公告）</p>\n<figure><img decoding=\"async\" height=\"249\" src=\"https://static.tigerbbs.com/56dbe5883ff7433198caa0638dc5d49e\" width=\"718\"/></figure>\n<p>（图片来源：NSB公告）</p>\n</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>收购MSC干细胞疗法技术引发股价暴涨 Neuroscientific Biopharmaceuticals (ASX:NSB) 加速克罗恩病临试研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n收购MSC干细胞疗法技术引发股价暴涨 Neuroscientific Biopharmaceuticals (ASX:NSB) 加速克罗恩病临试研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1080487607\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/6181633f5a87d6eb7ca4059b1fb9b32c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">澳洲财经见闻 </p>\n<p class=\"h-time\">2025-07-19 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>神经免疫疾病生物医学创新公司<strong>Neuroscientific Biopharmaceuticals Ltd (ASX股票代码:NSB) </strong>股价异动，周四飙涨16.67%。</p>\n<div>\n<div></div>\n</div>\n<p>自4月中旬披露收购间充质干细胞 (<a href=\"https://laohu8.com/S/NPW.SI\">MSC</a>) 治疗技术StemSmart以来，NSB股价上涨348.72%。</p>\n<p>NSB最新价0.175澳元，已发行股本3.33亿股，市值5820万澳元。截止一季度末公司账面现金结余449万澳元。</p>\n<p>美国FDA最近批准了首个MSC疗法——由市值达20亿澳元的澳洲生物科技公司<a href=\"https://laohu8.com/S/MESO\">Mesoblast</a>(ASX股票代码:MSB)提请注册，该进展重新点燃医疗界对MSC疗法临床研究的热情并吸引全球投资者目光。</p>\n<p>Neuroscientific Biopharmaceuticals 于6月底完成对StemSmart技术的收购。NSB即将上任的<strong>董事局主席Robert McKenzie</strong>表示，公司正在推动运用StemSmart治疗瘘管性克罗恩病的特别准入试验；若初步结果积极，将可推进至 1/2 期临试。</p>\n<figure><img decoding=\"async\" height=\"494\" src=\"https://static.tigerbbs.com/ec5e90405a53440890016f8c99cbe40b\" width=\"1024\"/></figure>\n<p>（图片来源：NSB公告）</p>\n<figure><img decoding=\"async\" height=\"249\" src=\"https://static.tigerbbs.com/56dbe5883ff7433198caa0638dc5d49e\" width=\"718\"/></figure>\n<p>（图片来源：NSB公告）</p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://afndaily.com/%e6%94%b6%e8%b4%admsc%e5%b9%b2%e7%bb%86%e8%83%9e%e7%96%97%e6%b3%95%e6%8a%80%e6%9c%af%e5%bc%95%e5%8f%91%e8%82%a1%e4%bb%b7%e6%9a%b4%e6%b6%a8-neuroscientific-biopharmaceuticals-asxnsb-%e5%8a%a0/","article_id":"2552154364","we_media_id":"1080487607","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552154364","pubTimestamp":1752892572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"澳洲财经见闻","introduction":"提供每日不可缺的商业财经新闻、深度分析以及评论。","home_visible":1,"id":"1080487607","head_image":"https://community-static.tradeup.com/news/6181633f5a87d6eb7ca4059b1fb9b32c"},"summary":"神经免疫疾病生物医学创新公司Neuroscientific Biopharmaceuticals Ltd (ASX股票代…","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK7067":"生物科技","BK4575":"芯片概念","NSB.AU":"NEUROSCIENTIFIC BIOPHARMACEU","BK4150":"赌场与赌博","MSC":"新濠影汇"},"translate_title":"Acquisition of MSC Stem Cell Therapy Technology Sparks Stock Price Spike Neuroscientific Biopharmaceuticals (ASX: NSB) Accelerates Crohn's Disease Trial Study","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSC":1,"NSB.AU":1},"content_text":"神经免疫疾病生物医学创新公司Neuroscientific Biopharmaceuticals Ltd (ASX股票代码:NSB) 股价异动，周四飙涨16.67%。\n\n\n\n自4月中旬披露收购间充质干细胞 (MSC) 治疗技术StemSmart以来，NSB股价上涨348.72%。\nNSB最新价0.175澳元，已发行股本3.33亿股，市值5820万澳元。截止一季度末公司账面现金结余449万澳元。\n美国FDA最近批准了首个MSC疗法——由市值达20亿澳元的澳洲生物科技公司Mesoblast(ASX股票代码:MSB)提请注册，该进展重新点燃医疗界对MSC疗法临床研究的热情并吸引全球投资者目光。\nNeuroscientific Biopharmaceuticals 于6月底完成对StemSmart技术的收购。NSB即将上任的董事局主席Robert McKenzie表示，公司正在推动运用StemSmart治疗瘘管性克罗恩病的特别准入试验；若初步结果积极，将可推进至 1/2 期临试。\n\n（图片来源：NSB公告）\n\n（图片来源：NSB公告）","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,productRelease,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}